Atara Biotherapeutics (ATRA) Receivables (2020 - 2026)
Atara Biotherapeutics' (ATRA) quarterly Receivables came in at $1.3 million in Q4 2025, down 15.45% YoY from $1.5 million in Q4 2024, and down 34.5% on a QoQ basis from $1.9 million in Q3 2025.
Atara Biotherapeutics (ATRA) Receivables (2020 - 2026) Analysis & Trends
Atara Biotherapeutics (ATRA) has 6 years of Receivables data on file, last reported at $1.3 million in Q4 2025.
- Quarterly Receivables fell 15.45% year-over-year to $1.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.3 million (down 15.45% YoY) and the FY2025 annual result came in at $1.3 million, down 15.45% from the prior year.
- Receivables slipped to $1.3 million in Q4 2025, from $1.9 million in the prior quarter.
- In the past five years, Receivables ranged from a high of $40.2 million in Q4 2022 to a low of $163000.0 in Q3 2023.
- A 5-year average of $8.3 million and a median of $1.3 million in 2024 frame the typical range for Receivables.
- The widest YoY moves for Receivables: up 8926.2% in 2024, down 95.65% in 2024.
- Tracing ATRA's Receivables over 5 years: stood at $986000.0 in 2021, then jumped by 3979.21% to $40.2 million in 2022, then dropped by 15.2% to $34.1 million in 2023, then sank by 95.65% to $1.5 million in 2024, then fell by 15.45% to $1.3 million in 2025.
- The last three Receivables figures came in at $1.3 million (Q4 2025), $1.9 million (Q3 2025), and $8.9 million (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.82 Bn | 131.97 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 65.27 Bn | 60.09 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 59.18 Bn | 54.04 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 42.11 Bn | 37.01 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn | 912.74 Mn |
| 7 | BioNTech SE | 28.14 Bn | 9.75 Bn | 668.28 Mn | 1.09 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 215.33 Mn |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - | - |
| 10 | Atara Biotherapeutics | 144.47 Mn | 127.92 Mn | 439,000.00 | 318,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 318,000.00 |
| Dec 31, 2025 | 1.25 Mn |
| Sep 30, 2025 | 1.91 Mn |
| Mar 31, 2025 | 8.88 Mn |
| Dec 31, 2024 | 1.48 Mn |
| Sep 30, 2024 | 1.34 Mn |
| Jun 30, 2024 | 2.42 Mn |
| Mar 31, 2024 | 35.83 Mn |
| Dec 31, 2023 | 34.11 Mn |
| Sep 30, 2023 | 163,000.00 |
| Jun 30, 2023 | 507,000.00 |
| Mar 31, 2023 | 397,000.00 |
| Dec 31, 2022 | 40.22 Mn |
| Sep 30, 2022 | 249,000.00 |
| Jun 30, 2022 | 637,000.00 |
| Mar 31, 2022 | 668,000.00 |
| Dec 31, 2021 | 986,000.00 |
| Mar 31, 2021 | 9.61 Mn |
| Dec 31, 2020 | 1.25 Mn |